The CD4 cell count at which combination antiretroviral therapy should be started is a central, unresolved issue in the care of HIV-1-infected patients.
-- When to Start Consortium, "Timing of Initiation of Antiretroviral Therapy in AIDS-free HIV-1 infected Patients: A Collaborative Analysis of 18 HIV Cohort Studies." Lancet 373;9672:1352-63, April 18, 2009.
Ever since the first anti-HIV drug was approved for prescription in 1987, there has been debate and controversy regarding when an HIV-positive person should start antiretroviral therapy (ART). Up until the mid-1990s, the question revolved around maximizing the limited benefits of treatment with one or two nucleoside analogue reverse transcriptase inhibitors (NRTIs) -- such as AZT, ddI, ddC, d4T, 3TC, and the like -- in temporarily staving off progression to AIDS. The advent of combination ART capable of prolonged -- and potentially lifelong -- suppression of HIV replication altered the landscape drastically, and now the focus is on the risks and benefits of earlier versus later treatment over decades. But for hundreds of thousands of HIV-positive people diagnosed at higher CD4 counts, this life-altering treatment decision has been fraught with uncertainty due to lack of the most reliable, rigorous evidence -- that derived from well-designed, controlled, randomized clinical trials.
In the United States, the task of synthesizing the available evidence and making recommendations on how to use ART falls to a panel of experts who issue regularly updated guidelines under the aegis of the U.S. Department of Health and Human Services (DHHS). In December 2009 the DHHS guidelines panel revised its recommendation on when to start ART, raising the threshold from less than 350 CD4 cells to less than 500. The panel was split over the strength of this specific recommendation, with 55% endorsing it strongly and 45% moderately. Half of the panel also went even further, offering a moderate recommendation to start ART at any CD4 level, with the other half considering this approach optional. (The revised guidelines are available online.)
This change to the DHHS guidelines has generated controversy for a number of reasons. Most prominently, there is ongoing debate over the quality of the scientific evidence available to address the effect of starting ART at different CD4 cell count thresholds. The gold standard for evidence is the randomized controlled trial (RCT), in which individuals with very similar characteristics are randomly assigned to different interventions or strategies. In the absence of results from RCTs, data obtained from large cohorts of people with HIV in medical care is the most common secondary source of evidence. However, cohort studies are notoriously subject to a problem called confounding bias; a confounder is a factor associated with the outcome of interest that the study fails to capture. As an example, it could be that a member of a cohort who starts ART early has other factors associated with better health -- such as access to private insurance and lower copays, or greater health-seeking behavior -- and these factors could be more important to the study outcome than ART. Conversely, a cohort member who starts ART late may have risk factors for illness that the study fails to capture.
Without information on all potential confounders, as well as information on any negative aspects of HAART [highly active antiretroviral therapy] when initiated at higher CD4 cell counts, the benefit-to-risk ratio for early use of antiretroviral therapy remains unknown and we must await data from large RCTs [randomized clinical trials] before final conclusions can be reached.
-- Caroline Sabin, "Cohort studies: to what extent can they inform treatment guidelines." Curr Opin Infect Dis. 23;1:15-20, December 4, 2009.
There is virtually no evidence from RCTs of when to start ART among ART-naive individuals starting treatment with CD4 counts over 350/mm3. Most of the evidence cited in support of the new DHHS recommendations is derived not from RCTs but from two published meta-analyses of data from multiple large cohort studies, with additional support from smaller studies of HIV pathogenesis, particularly those describing harmful long-term effects of HIV-induced inflammation. A community sign-on letter addressed to the DHHS guidelines panel has expressed concern that the change could inadvertently make it more difficult to complete a critically important RCT that is being conducted by the INSIGHT network expressly to address the when-to-start question; this trial (known as START) is in a pilot phase and aims to compare initiation of ART at a CD4 cell count over 500 to deferral to a count of less than 350 cells (http://i-base.info/files/2010/05/CABStatementOnSTART.pdf).
Concerns about prevention have brought an additional wrinkle: for the first time, the DHHS guidelines note that suppression of viral load by ART is associated with a greatly reduced risk of transmitting HIV. This has caused some people to fear that the push to recommend earlier treatment is being made to prevent new infections. Despite the lack of conclusive evidence for clinical benefit to the individuals who will be initiating treatment for their own HIV infection.
Sorting though the tangle of issues now caught up in the when-to-start question is not easy. As a base line, there is widespread consensus that ART should be initiated when CD4 counts drop below 350, and this recommendation is supported by data from cohort studies and results from an RCT that were presented in 2009. The study, called CIPRA HT 001, enrolled 816 individuals in Haiti and compared starting ART with a CD4 count between 200 and 350 to deferring until the CD4 count fell below 200. An interim analysis revealed that deferral was associated with a significantly increased risk of illness and death and the differences were so stark (23 deaths in the deferred group versus 6 in the immediate group) that the trial was stopped by the Data Safety Monitoring Board.
At CD4 levels above 350, uncertainty intrudes. The only randomized data available are derived from a subset of participants in the Strategies for the Management of Antiretroviral therapy (SMART) trial, which was an evaluation of intermittent versus continuous ART. Two hundred and forty-nine people (out of a total of 5,472 participants) entered the study with >350 CD4 cells, having never taken ART. Of these, 131 were randomized to start ART immediately while 118 deferred until CD4 counts were lower than 250. Over an average follow-up of 18 months, there were seven cases of serious illness or death among people who deferred ART compared to two among people who started immediately. There was only one death, which occurred in the deferral group and was caused by cardiovascular disease. Because there were too few people in this subset for the results to reach statistical significance, the researchers conducted analyses that included individuals who had taken ART in the past but had been off for more than six months when they enrolled in SMART. With this group included, the difference in illnesses and deaths between the deferred and immediate groups became statistically significant, increasing the totals to 21 versus 6 events. The result was also significant if only those participants who had been off ART for at least a year were considered. However, there were some modest differences between participants who had never taken ART and the added group of those who had interrupted treatment. Members of the latter group were three years older on average and were more likely to have certain additional risk factors for illness (such as smoking) despite comparable CD4 cell counts (both current and the lowest levels ever reached). These factors may have exacerbated the risks associated with deferring ART. The authors of the paper describing these subset analyses from SMART (which was published in the Journal of Infectious Diseases in 2008) take pains to stress that the results are exploratory and need to be confirmed by an RCT.
The main evidence cited in support of the new DHHS recommendation to start at >350 CD4 cells comes from a large cohort study called NA-ACCORD (a "cohort of cohorts" that collates data from a number of smaller cohorts). In an influential paper published in the New England Journal of Medicine in 2009, researchers reported that cohort members who started ART at either >350 CD4 cells or >500 cells faced a significantly lower risk of death compared to those who deferred. It's important to stress that, as with the SMART analysis described previously, the risk of death during follow-up was very low even among those who deferred. What the researchers emphasize is that the relative risk was significantly different, and this difference is expressed in terms that can easily mislead; for example, waiting until a CD4 count was below 500 was said to increase risk 94% compared to starting at above 500, and some people mistakenly interpreted this as suggesting that delaying ART meant death was a near certainty. However, in this context a 94% increase means roughly a doubling in risk, which for those with a CD4 count above 500 was relatively low (1.3 deaths per 100 person years, or approximately 13 deaths out of every 1, 000 people followed for a year).
No comments have been made.